Delphi advisor to Immunicum in connection with rights and directed issue

Advokatfirman Delphi has acted as legal advisor to Immunicum AB in connection with a rights issue and directed issue of approximately SEK 350 million. The share issues allow for further investments in order to enable Immunicum’s clinical development programs to reach several well-defined and potentially value-creating milestones. In addition, the ownership is strengthened with reputable institutional investors, including the Fourth AP Fund, Gladiator, the Second AP Fund, Alfred Berg, Nordic Cross and Adrigo.

Immunicum is a biopharmaceutical company that develops immune therapies against a range of solid tumors. Immunicum’s approach allows for an off-the-shelf product, based on a type of immune cell called dendritic cells that are designed to stimulate a personalized anti-tumor immune response in each patient.

Erik Penser Bank has acted as financial advisor in connection with the issue.

Delphi’s team consisted of Mats Dahlberg as responsible partner, assisted by Jenny Lindén, Clara Jarbrand and Fredrik Nykvist.